Allianz SE grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 94,654 shares of the company’s stock after buying an additional 5,216 shares during the period. Allianz SE’s holdings in Johnson & Johnson were worth $25,059,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Texas Yale Capital Corp. increased its holdings in shares of Johnson & Johnson by 6.5% in the 3rd quarter. Texas Yale Capital Corp. now owns 38,395 shares of the company’s stock worth $10,165,000 after buying an additional 2,358 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in shares of Johnson & Johnson by 1.4% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 9,588 shares of the company’s stock worth $2,538,000 after purchasing an additional 131 shares during the period. Intesa Sanpaolo Wealth Management raised its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. Intesa Sanpaolo Wealth Management now owns 9,867 shares of the company’s stock valued at $2,612,000 after acquiring an additional 130 shares in the last quarter. Cornerstone Select Advisors LLC grew its holdings in shares of Johnson & Johnson by 8.2% during the 3rd quarter. Cornerstone Select Advisors LLC now owns 4,435 shares of the company’s stock worth $1,174,000 after acquiring an additional 335 shares during the period. Finally, Fort Sheridan Advisors LLC lifted its stake in shares of Johnson & Johnson by 0.8% in the 3rd quarter. Fort Sheridan Advisors LLC now owns 50,999 shares of the company’s stock valued at $13,502,000 after purchasing an additional 410 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson News Summary
Here’s some of the latest news about JNJ:
- Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
- Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article
Insider Transactions at Johnson & Johnson
Analyst Ratings Changes
JNJ has been the subject of several recent research reports. Evercore set a $300.00 target price on shares of Johnson & Johnson in a report on Tuesday, October 20th. Citigroup upped their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. HSBC raised their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Leerink Partners cut their price target on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Finally, Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $276.54.
View Our Latest Report on Johnson & Johnson
Johnson & Johnson Trading Up 1.3%
Shares of JNJ opened at $270.54 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a market cap of $651.27 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. The firm’s fifty day moving average is $267.53 and its two-hundred day moving average is $250.98. Johnson & Johnson has a 52-week low of $199.90 and a 52-week high of $290.25.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter last year, the firm earned $2.80 EPS. The business’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
- Five stocks we like better than Johnson & Johnson
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
